Chronic Myeloid Leukemia, Chronic Phase Clinical Trials

27 clinical trials for Chronic Myeloid Leukemia, Chronic Phase across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia — RECRUITING · PHASE2
• A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) — RECRUITING · PHASE1
• PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML — RECRUITING · PHASE2
• Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase — RECRUITING
• A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs — RECRUITING · PHASE3
• Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase — ACTIVE_NOT_RECRUITING · PHASE2
• Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second or Subsequent Lines — NOT_YET_RECRUITING
• Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors — ACTIVE_NOT_RECRUITING · PHASE2
• A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase — COMPLETED · PHASE2
• Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP) — ACTIVE_NOT_RECRUITING · PHASE2
• Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) — ACTIVE_NOT_RECRUITING · PHASE3
• Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib — COMPLETED
• The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia — OTHER
• Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose — OTHER
• A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I Mutation — OTHER · PHASE2
• Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients — COMPLETED
• Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia — OTHER · PHASE2
• "Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker" — OTHER
• Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs. — OTHER · PHASE3
• Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia — TERMINATED · PHASE1
• Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure — OTHER · PHASE4
• Nilotinib for First-line Newly Diagnosed CML-CP Patients — OTHER · PHASE3
• Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia — COMPLETED · PHASE1
• Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia — TERMINATED · PHASE3
• Efficacy and Safety of Nilotinib in CML-CP — COMPLETED · PHASE4
• Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan — COMPLETED

Refine this search